Sarepta Therapeutics, Inc. Stock News

Sarepta Therapeutics said on Friday it would temporarily halt three trials testing its gene therapy Elevidys.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy. Following the safety update on acute liver failure that was issued on March 18, European Union (EU...

Sarepta stock plunged Thursday after European officials put all studies of the company's gene therapy, Elevidys, on hold. The post Sarepta Plunges After EMA Puts Gene Therapy Studies On Hold Following Teen's Death appeared first on Investor's Business Daily.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2025 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 39 individuals hired by Sarepta...

Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies.

Things are going from bad to worse for Sarepta Therapeutics (SRPT 0.84%), a biotech focusing on gene therapies. The company's performance over the past six months had already been unimpressive.

Shares of Sarepta Therapeutics dropped 20% after a patient died from acute liver injury post-ELEVIDYS treatment, an event not previously reported. Despite the tragic news, we believe this is an isolated incident, influenced by the patient's recent CMV infection, and not indicative of systemic issues. With over 800 patients treated and no similar cases, we expect the stock to recover, presenting...

Investors can contact the law firm at no cost to learn more about recovering their losses